LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC)
Clinical trials for LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC) explained in plain language.
Never miss a new study
Get alerted when new LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC) trials appear
Sign up with your email to follow new studies for LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to fight lung cancer after chemoradiation
Disease control Recruiting nowThis phase 2 trial is testing whether adding the drug QL1706 to standard chemotherapy and radiation can help people with limited-stage small cell lung cancer. QL1706 is a type of immunotherapy that targets two immune checkpoints to help the body fight cancer. The study will enrol…
Matched conditions: LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC)
Phase: PHASE2 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Triple therapy takes on tough lung cancer
Disease control Recruiting nowThis phase II trial tests whether adding two drugs—toripalimab (an immunotherapy) and surufatinib (a targeted therapy)—to standard chemoradiation can help people with limited-stage small cell lung cancer live longer without the disease getting worse. About 47 adults aged 18–75 wi…
Matched conditions: LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC